Moderna Inc. ($MRNA) Stock Forecast: Up 7.5% Today

What is Moderna Inc.?

Moderna, Inc. (NASDAQ: MRNA) is a biotechnology company known for its innovative mRNA technology, particularly in the development of vaccines.

Why is Moderna Inc. going up?

MRNA stock is up 7.5% on Apr 15, 2026 13:40

• Moderna saw strong bullish movement today possibly due to the positive expectations surrounding its upcoming first-quarter 2026 financial results.
• The company's scheduled live conference call and webcast discussing financial results and future plans may have boosted investor confidence.
• Investor interest remains high in the biotech and healthcare sectors, exemplified by Moderna's positive market response in comparison to developments in other companies.
• Moderna's active engagement with investors and market optimism regarding its financial results likely contributed to the bullish movement in its stock price today.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

Moderna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026

Moderna, Inc. (NASDAQ:MRNA) announced it will host a live conference call and webcast on Friday, May 1, 2026, at 8:00 a.m. ET to report its first-quarter 2026 financial results. The event will also include a corporate update and a live webcast will be available in the Investors section of Moderna's website.

https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/moderna-to-report-first-quarter-2026-financial-results-on-friday-may-1156991

Moderna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026

Moderna, Inc. (NASDAQ:MRNA) announced it will report its first quarter 2026 financial results on Friday, May 1, 2026. The biotech company will host a live conference call and webcast at 8:00 a.m. ET to discuss the results and provide a corporate update. The webcast will be available on Moderna's investor relations website, and an archived version will be accessible for one year.

https://www.marketscreener.com/news/moderna-to-report-first-quarter-2026-financial-results-on-friday-may-1-2026-ce7e50dcda80f52c

Moderna schedules May 1 webcast for first-quarter 2026 results

Moderna (NASDAQ: MRNA) announced it will report its first-quarter 2026 financial results on Friday, May 1, 2026, with a live conference call and webcast at 8:00 a.m. ET. The company will also provide a corporate update during the call, with an archived webcast available two hours later for one year. This announcement follows a historical pattern for scheduling earnings calls, which has typically resulted in limited short-term stock price impact.

https://www.stocktitan.net/news/MRNA/moderna-to-report-first-quarter-2026-financial-results-on-friday-may-2wcdd8mmtgu4.html

Sanofi Expands Respiratory Portfolio With Nuvaxovid Role And Lunsekimig Data

Sanofi is expanding its respiratory health portfolio by becoming the market authorization holder for Nuvaxovid, a non-mRNA COVID-19 vaccine, in Canada. The company also announced positive Phase 2 results for Lunsekimig in treating asthma and chronic rhinosinusitis with nasal polyps, suggesting a broad target population if future trials are successful. These developments enhance Sanofi's presence in vaccines and therapeutics, though investors should consider the execution risk for new product integration.

https://simplywall.st/stocks/fr/pharmaceuticals-biotech/epa-san/sanofi-shares/news/sanofi-expands-respiratory-portfolio-with-nuvaxovid-role-and

Qiagen N.V. stock (NL0012169213): Why does its sample-to-insight business model matter more for U.S.

Qiagen N.V.'s "sample-to-insight" business model is increasingly relevant for US investors due to its focus on automated solutions for molecular diagnostics and research, directly supporting precision medicine. This model provides exposure to stable demand from labs and pharma, emphasizing scalable automation and recurring revenue from consumables. Analysts view this approach favorably for its resilience, competitive moat, and alignment with high-growth areas like genomics and infectious disease testing.

https://www.ad-hoc-news.de/boerse/news/ueberblick/qiagen-n-v-stock-nl0012169213-why-does-its-sample-to-insight-business/69154718

Trending Today

Heating Oil ($HEATOIL) Commodity Forecast: Up 5.2% Today

Chewy Inc ($CHWY) Stock Forecast: Up 5.2% Today

Cadence Design Systems Inc. ($CDNS) Stock Forecast: Up 5.2% Today

Fortune Brands Innovations Inc. ($FBIN) Stock Forecast: Down 5.3% Today

A.O. Smith Corporation ($AOS) Stock Forecast: Down 6.4% Today

Credo Technology Group ($CRDO) Stock Forecast: Up 5.6% Today

Live Nation Entertainment Inc. ($LYV) Stock Forecast: Down 5.5% Today

Coinbase Global Inc. ($COIN) Stock Forecast: Up 5.4% Today

Tesla Inc. ($TSLA) Stock Forecast: Up 7.4% Today

V.F. Corporation ($VFC) Stock Forecast: Up 5.0% Today

Moderna Inc. Price History

02.03.2026 - MRNA Stock was down 5.2%

• Moderna's decline in stock value could be linked to concerns regarding slow enrollment in COVID-19 vaccine trials, mirroring issues observed with Pfizer and BioNTech. This trend suggests potential difficulties in gathering post-marketing data and a waning interest in COVID-19 vaccines.
• The temporary pause in vaccine trial enrollment may have instilled uncertainty among investors concerning the vaccine development timeline and regulatory clearance, resulting in a negative impact on Moderna's stock performance.
• Investor attention appears to be shifting towards other biotech entities such as Allogene Therapeutics, benefiting from positive sector trends and experiencing a rise in stock prices. This redirection of focus and investment away from Moderna potentially contributed to its recent decline.

02.03.2026 - MRNA Stock was down 5.7%

• Moderna's stock experienced a bearish movement today, possibly influenced by:
• Pfizer and BioNTech halting enrollment in a large U.S. COVID-19 vaccine trial due to slow recruitment, reflecting potential challenges and decreased interest in vaccine trials.
• Market sentiment shifting towards Allogene Therapeutics, which is gaining momentum in the biotechnology sector with positive clinical pipeline developments, diverting attention from Moderna.
• Mixed trade ideas and technical analyses on Moderna's stock from traders, indicating uncertainty and varied perspectives on its future movements.
• The bearish trend in Moderna's stock today could be a result of concerns regarding vaccine trial enrollment, competition in the biotech sector, and divergent market analyses, leading to a decline in investor confidence in the short term.

18.02.2026 - MRNA Stock was down 5.1%

• Moderna's stock declined by 3.77% today.
• Institutional selling pressure, specifically with one entity reducing its stake, has impacted the stock causing short-term uncertainty.
• Despite exceeding earnings expectations and receiving positive feedback on its mRNA flu vaccine from regulatory authorities, the stock is facing a downward trend due to conflicting technical indicators and expert opinions.
• Market sentiment towards Moderna remains cautious as worries about potential risks outweigh recent company achievements and progress in precision medicine.

18.02.2026 - MRNA Stock was down 5.7%

• Moderna Inc. (MRNA) encountered a downward trend in the market today, grappling with obstacles related to its pipeline projects and financial pressures.
• Factors such as decreased demand for its COVID-19 vaccine, Spikevax, and scrutiny surrounding its pipeline advancements have influenced the stock's downturn.
• Investors are reassessing the company's future prospects as Moderna transitions focus towards diverse therapies like mRNA oncology and rare diseases, causing uncertainties in the market.
• Despite holding a substantial cash reserve, notable R&D expenses, and varied efficacy outcomes in certain trials, Moderna's stock performance has been adversely affected by the challenges it is currently facing.

01.03.2026 - MRNA Stock was up 5.3%

• The recent upward trend in Moderna's stock price can be linked to its strategic shift towards oncology research and the development of next-gen respiratory solutions, underscoring a focus on sustained growth opportunities extending beyond the realm of pandemic-related vaccines.
• Investor enthusiasm is likely fueled by Moderna's dedicated efforts in oncology, particularly the promising outcomes in personalized neoantigen therapy for melanoma, signaling positive market responses to the company's diversification.
• Moderna's target of achieving profitability by 2028, backed by a substantial cash reserve and a recent legal settlement, instills further confidence among investors regarding the company's trajectory.
• Noteworthy progress in resolving the ongoing patent dispute with Arbutus Biopharma Corp (ABUS) may have also contributed to the positive momentum of Moderna's stock, as a favorable resolution in legal matters could help alleviate uncertainties for stakeholders.

27.02.2026 - MRNA Stock was down 6.0%

• Moderna's stock (MRNA) faced a bearish movement, potentially attributed to profit-taking following a period of strong performance.
• Despite being a key player in the biotech industry and expanding its pipeline, investors may have reacted cautiously to potential challenges in the vaccine market and broader biotech sector.
• The company's shift towards treatments for respiratory viruses, oncology, and rare diseases may not have immediately captured market optimism, contributing to the bearish movement.
• The market's trajectory could also be influenced by general sector trends or broader economic factors impacting investor sentiment towards biotech stocks.

27.02.2026 - MRNA Stock was down 5.1%

• Moderna's stock experienced a significant drop today, possibly influenced by the broader market sentiment affected by the U.S.-Iran conflict and policy deadlines.
• The internal realignment by Vanguard, resulting in 0 reported shares, might have also contributed to the downward pressure on Moderna's stock.
• Despite ongoing growth potential from strategic partnerships and promising pipelines, the stock faced short-term selling pressure, reflecting investor concerns.
• The market's negative reaction to the overall uncertainty and rising oil prices could have led to the decline in Moderna's stock, creating potential buying opportunities for investors eyeing high-quality stocks.

27.02.2026 - MRNA Stock was down 5.2%

• A realignment announcement by Vanguard of 0 MRNA shares might have created uncertainty among investors, leading to a sell-off of Moderna stock.
• The comparison between ImmunityBio and Moderna, highlighting Moderna's broader pipeline and financial stability, could have influenced investors to shift their focus towards ImmunityBio, impacting Moderna's stock price negatively.
• Despite being a leading player in the biotech sector and strategically diversifying its pipeline, Moderna's stock might have faced downward pressure due to concerns about the company's ability to sustain growth beyond its COVID-19 vaccine.
• The potential for significant growth over the next five years for Moderna might not have been enough to offset the immediate bearish sentiment surrounding the stock today.

08.03.2026 - MRNA Stock was up 5.5%

• Moderna's surge in the market may be linked to optimistic views on its international COVID-19 vaccine markets, emphasized by analysts. Expectations of substantial gains from deals like the UK's COVID booster program and future post-pandemic market agreements have spurred investor confidence.
• Despite reduced forecasts for its RSV vaccine, the heightened revenue projections for Moderna's COVID-19 vaccines by analysts at the bank have likely instilled faith in the company's growth prospects among investors.
• The upbeat market reception to Moderna's potential expansion in global markets may have overshadowed the reservations raised by the 'Underperform' rating and $31 price target set by analysts. This hints at a disparity between analyst evaluations and market sentiments.

08.03.2026 - MRNA Stock was up 6.7%

• Moderna saw a significant rise in its stock price following an increase in price target to $35 from $30 by RBC Capital Markets, while maintaining a "Sector Perform" rating.
• This optimistic forecast signifies the market's confidence in Moderna's potential growth within the biotech sector.
• Analyst revisions, including the raised price target, indicate sustained interest and positivity towards Moderna's pipeline and future developments.
• The general positive sentiment towards Moderna may also be influenced by the broader optimistic outlook on biotech firms and healthcare technology progress, driving investor enthusiasm towards innovative solutions such as mRNA-based therapies.

31.02.2026 - MRNA Stock was up 5.3%

• The positive investor sentiment towards the company's strategic shift towards oncology and next-generation therapies is likely the driving force behind the recent bullish movement of the company's stock.
• Favorable data on individualized neoantigen therapy for melanoma and the company's emphasis on cancer drug development are factors contributing to the market's positive response to the company's new direction.
• The selling of shares by an insider at a different company may have indirectly impacted the company's stock positively, potentially leading investors to view the company's strategic pivot more favorably.
• The company's proactive approach to diversifying its portfolio and focusing on innovative therapies appears to have resonated well with investors, leading to the upward movement in its stock price.

15.03.2026 - MRNA Stock was up 7.5%

• Moderna saw strong bullish movement today possibly due to the positive expectations surrounding its upcoming first-quarter 2026 financial results.
• The company's scheduled live conference call and webcast discussing financial results and future plans may have boosted investor confidence.
• Investor interest remains high in the biotech and healthcare sectors, exemplified by Moderna's positive market response in comparison to developments in other companies.
• Moderna's active engagement with investors and market optimism regarding its financial results likely contributed to the bullish movement in its stock price today.